Given the results of the GETUG 14 randomized trial presented at ASCO 2016, should all men with intermediate-risk prostate cancer receiving dose-escalated radiotherapy receive concurrent ADT?   

In this abstract the 5-year probability of survival without clinical/biochemical relapse was significantly improved with ADT.



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice